2022 World Conference on Lung Cancer (ePosters)-EP05.02-019. Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Surgical Outcomes in a Regionalized Pulmonary Oncology Network

EP05.02-019. Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Surgical Outcomes in a Regionalized Pulmonary Oncology Network

Back to course

Pdf Summary

This study aimed to evaluate the safety and feasibility of transitioning to neoadjuvant therapy (NAT) for resectable non-small cell lung cancer (NSCLC) within a regionalized pulmonary oncology network. The researchers analyzed the peri-operative outcomes of patients who received NAT compared to those who underwent upfront surgery. They also assessed the risk factors for developing post-operative complications.<br /><br />The study included patients with clinical stage II-III NSCLC who underwent surgery at a University based unit from 2015-2020. Peri-operative outcomes and surgical complications were compared between patients who received NAT and those who underwent upfront surgery. The severity of post-operative complications was classified according to a validated grading system.<br /><br />The results showed that there were no significant differences in peri-operative outcomes between patients who received NAT and those who underwent upfront surgery. The study demonstrated that transitioning towards a neoadjuvant therapy program for operable NSCLC patients is safe and feasible from a surgical perspective.<br /><br />The study also illustrated the diversity of neoadjuvant regimens administered to patients with clinical stage II-III NSCLC. From 2015 to 2020, 25% of all operable clinical stage II-III NSCLC patients at the McGill University Health Center received neoadjuvant therapy.<br /><br />In conclusion, the study provides evidence that a large-scale neoadjuvant therapy program can be safely and feasibly implemented for patients with resectable NSCLC. The findings support the use of NAT for downstaging tumors and evaluating pathological response before surgery in locally advanced NSCLC. The study contributes to the evolving care patterns for resectable locally advanced NSCLC within a regionalized pulmonary oncology network.

Asset Subtitle

Yohann Pilon

Meta Tag

Speaker Yohann Pilon

Topic Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy

Keywords

neoadjuvant therapy

resectable non-small cell lung cancer

NSCLC

peri-operative outcomes

upfront surgery

post-operative complications

clinical stage II-III

surgical complications

validated grading system

neoadjuvant regimens